WINDLAS BIOTECH Latest Share Price (WINDLAS)
TODAY IN ONE LINE
WINDLAS fell 3.0% on above-average volume (2.5x avg), lagging Nifty's -1.6% move.
With a market cap of ₹2,062.9 Cr., it trades at a P/E of 43.20. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
WINDLAS BIOTECH flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.05x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 2.6% YoY
- ●Rising Receivables vs SalesReceivables grew 46.1% outpacing sales growth of 20.4%
Latest WINDLAS BIOTECH News
What changed recently?
Recent events, corporate actions, and announcements.
WINDLAS BIOTECH valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for WINDLAS BIOTECH, framed against the sector median so the premium or discount is obvious at a glance.
WINDLAS BIOTECH trades at a P/E of 43.20× and P/B of 3.63×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
WINDLAS BIOTECH technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for WINDLAS BIOTECH — derived from the latest tape, not yesterday's close.
WINDLAS BIOTECH last traded at ₹991.6 with an intraday range of ₹979.6–₹1,024.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹991.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1107.33 | +115.73 | +11.67% |
| R3 | 1062.43 | +70.83 | +7.14% |
| R2 | 1043.47 | +51.87 | +5.23% |
| R1 | 1017.53 | +25.93 | +2.62% |
| PIVOT | 998.57 | 6.97 | 0.70% |
| CURRENT | 991.60 | — | — |
| S1 | 972.63 | -18.97 | -1.91% |
| S2 | 953.67 | -37.93 | -3.83% |
| S3 | 927.73 | -63.87 | -6.44% |
| S4 | 882.83 | -108.77 | -10.97% |
WINDLAS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹995–₹1024.5
Trading Below opening range, showing Bearishness
WINDLAS BIOTECH financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for WINDLAS BIOTECH — consolidated or standalone — with margins, YoY growth and key ratios inline.
WINDLAS BIOTECH reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,062.9 Cr. and reported EPS of ₹8.55.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 760 | 904 ▲ 19.0% |
| Sales Growth YoY %Derived | 20.43% | 18.98% |
| Other Income | 18 | 18 ▼ 1.2% |
| Total Income | 778 | 922 ▲ 18.5% |
| 472 | 557 ▲ 18.1% | |
| Gross ProfitDerived | 288 | 347 ▲ 20.4% |
| Gross Margin %Derived | 37.90% | 38.37% |
| 194 | 242 ▲ 24.9% | |
| EBITDA (Operating Profit)Derived | 94 | 105 ▲ 11.3% |
| OPM %Derived | 12.38% | 11.59% |
| 32 | 36 ▲ 9.9% | |
| Profit Before Tax (PBT) | 80 | 87 ▲ 9.1% |
| 19 | 21 ▲ 9.4% | |
| Effective Tax %Derived | 23.53% | 23.59% |
| Total Profit for Period | 61 | 66 ▲ 9.0% |
| Net Profit (Owner's PAT)Derived | 61 | 66 ▲ 9.0% |
| Net Profit Margin %Derived | 8.03% | 7.35% |
| PAT Growth YoY %Derived | 4.82% | 8.95% |
| Earnings Per Share (EPS ₹) | 29.10 | 31.49 ▲ 8.2% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.7% |
| Other Comprehensive Income (Net of Tax) | -1 | 0 ▲ 120.2% |
| Total Expenses (incl. D&A & Interest) | 698 | 835 ▲ 19.6% |
| Material Cost % of RevenueDerived | 0.31% | 1.38% |
| Employee Cost % of RevenueDerived | 16.18% | 16.82% |
| Other Cost % of RevenueDerived | 9.34% | 9.96% |
| Interest Coverage (x)Derived | 15.09x | 15.33x |
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|
| Revenue from Operations | 466 | 513 ▲ 10.1% | 631 ▲ 23.0% | 760 ▲ 20.4% | 904 ▲ 19.0% | |
| Sales Growth YoY %Derived | — | 10.12% | 22.97% | 20.43% | 18.98% | |
| Other Income | 7 | 10 ▲ 48.6% | 13 ▲ 35.2% | 18 ▲ 33.8% | 18 ▼ 1.2% | |
| Total Income | 473 | 523 ▲ 10.7% | 644 ▲ 23.2% | 778 ▲ 20.7% | 922 ▲ 18.5% | |
303 | 325 ▲ 7.5% | 396 ▲ 21.7% | 472 ▲ 19.1% | 557 ▲ 18.1% | ||
| Gross ProfitDerived | 163 | 188 ▲ 15.0% | 235 ▲ 25.1% | 288 ▲ 22.7% | 347 ▲ 20.4% | |
| Gross Margin %Derived | 35.01% | 36.57% | 37.21% | 37.90% | 38.37% | |
111 | 127 ▲ 15.1% | 157 ▲ 22.9% | 194 ▲ 23.8% | 242 ▲ 24.9% | ||
| EBITDA (Operating Profit)Derived | 52 | 60 ▲ 14.9% | 78 ▲ 29.8% | 94 ▲ 20.4% | 105 ▲ 11.3% | |
| OPM %Derived | 11.25% | 11.74% | 12.39% | 12.38% | 11.59% | |
14 | 13 ▼ 3.0% | 15 ▲ 10.6% | 32 ▲ 122.5% | 36 ▲ 9.9% | ||
| Profit Before Tax (PBT) | 46 | 57 ▲ 25.2% | 77 ▲ 35.2% | 80 ▲ 3.5% | 87 ▲ 9.1% | |
7 | 14 ▲ 92.8% | 19 ▲ 31.2% | 19 ▼ 0.7% | 21 ▲ 9.4% | ||
| Effective Tax %Derived | 16.41% | 25.27% | 24.52% | 23.53% | 23.59% | |
| Total Profit for Period | 38 | 43 ▲ 11.9% | 58 ▲ 36.5% | 61 ▲ 4.8% | 66 ▲ 9.0% | |
| Net Profit (Owner's PAT)Derived | 38 | 43 ▲ 11.9% | 58 ▲ 36.5% | 61 ▲ 4.8% | 66 ▲ 9.0% | |
| Net Profit Margin %Derived | 8.17% | 8.31% | 9.22% | 8.03% | 7.35% | |
| PAT Growth YoY %Derived | — | 11.91% | 36.51% | 4.82% | 8.95% | |
| Earnings Per Share (EPS ₹) | 17.39 | 20.35 ▲ 17.0% | 27.98 ▲ 37.5% | 29.10 ▲ 4.0% | 31.49 ▲ 8.2% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▼ 3.9% | 2 ▼ 0.7% | 2 ▲ 0.8% | 2 ▲ 0.7% | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▲ 1.6% | -0 ▼ 35.5% | -1 ▼ 121.4% | 0 ▲ 120.2% | |
| Total Expenses (incl. D&A & Interest) | 427 | 466 ▲ 9.1% | 567 ▲ 21.7% | 698 ▲ 23.1% | 835 ▲ 19.6% | |
| Material Cost % of RevenueDerived | 66.01% | -0.15% | 0.47% | 0.31% | 1.38% | |
| Employee Cost % of RevenueDerived | 13.61% | 13.71% | 13.86% | 16.18% | 16.82% | |
| Other Cost % of RevenueDerived | 10.15% | 11.13% | 10.96% | 9.34% | 9.96% | |
| Interest Coverage (x)Derived | 28.42x | 60.74x | 58.58x | 15.09x | 15.33x |
WINDLAS BIOTECH segment analysis : revenue and profit mix.
Disclosed business segments at WINDLAS BIOTECH with their share of revenue and profit, switchable between consolidated and standalone reporting.
WINDLAS BIOTECH discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for WINDLAS BIOTECH.
Our AI distills the core fundamental drivers supporting WINDLAS BIOTECH, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
WINDLAS BIOTECH's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 56 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.31%.
WINDLAS BIOTECH peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — WINDLAS BIOTECH is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
WINDLAS BIOTECH chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for WINDLAS BIOTECH — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
WINDLAS BIOTECH delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for WINDLAS BIOTECH over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in WINDLAS BIOTECH stood at 52.3% of traded volume, against a 20-day average of 49.5%.
WINDLAS BIOTECH announcements: results, concalls, ratings, M&A.
Filings WINDLAS BIOTECH sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
WINDLAS BIOTECH files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 98 documents below.
Trading Window
Windlas Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited has informed the Exchange about earnings call transcript of Q1 FY27
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited has informed the Exchange about Link of Recording
Press Release
Windlas Biotech Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "press release on "Windlas Biotech Limited…
Investor decks & rating reports.
WINDLAS BIOTECH dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue WINDLAS BIOTECH has declared, sequenced by announce and record date.
WINDLAS BIOTECH corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About WINDLAS BIOTECH: business, sector, key facts.
What WINDLAS BIOTECH does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
WINDLAS BIOTECH operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: WINDLAS, BSE: 543329.
Windlas Biotech Limited is a prominent contract development and manufacturing organization (CDMO) operating in the pharmaceutical industry, both domestically within India and on a global scale. Their core business revolves around providing comprehensive CDMO solutions to other pharmaceutical companies, encompassing the entire lifecycle from initial product development and securing necessary licenses to the large-scale commercial manufacturing of diverse pharmaceutical products.
The company specializes in the production of complex drugs and various dosage forms, demonstrating a high level of technical expertise and manufacturing capabilities. This expertise extends to a wide range of pharmaceutical products including tablets, capsules, pouches, sachets, and liquid bottles. Their manufacturing capabilities are not limited to simple formulations, they also handle more intricate formulations such as fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and specialized formats like chewable or dispersible tablets, and plain oral solid dosage forms.
Beyond its CDMO services, Windlas Biotech also has a significant presence in the manufacturing and trading of generic pharmaceutical products. This further diversifies their revenue streams and establishes them as a key player within the broader Indian and international pharmaceutical market. Their portfolio of generic products caters to a wide range of therapeutic needs, solidifying their position as a reliable supplier of affordable and accessible medications.
In addition to traditional pharmaceuticals, Windlas Biotech also engages in the production of nutraceutical supplement products, highlighting their adaptability and expansion into related health and wellness markets. This diversification strategy allows the company to tap into growing consumer demand for health-enhancing supplements, further broadening their product range and market reach. This strategic diversification demonstrates their commitment to growth and innovation within the broader healthcare industry.
Established in 2001 and headquartered in Gurugram, India, Windlas Biotech Limited has built a strong reputation based on its expertise in complex pharmaceutical manufacturing, comprehensive CDMO services, and diverse product portfolio. This combination of factors positions the company for continued success and growth in the dynamic and ever-evolving global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about WINDLAS BIOTECH (WINDLAS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of WINDLAS BIOTECH (WINDLAS)?
The current share price of WINDLAS BIOTECH (WINDLAS) is ₹991.60. Today, the stock has declined by ₹30.40 (2.97%), trading in a range of ₹979.60 to ₹1,024.50. The stock opened at ₹1,018.40 with a trading volume of 1,22,795 shares.
02Is WINDLAS BIOTECH stock a good investment for long-term?
WINDLAS BIOTECH can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,062.9 Cr., P/E ratio of 43.2, ROE of 11.44%, and ROCE of 11.49%. The dividend yield stands at 0.62%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of WINDLAS BIOTECH stock?
The 52-week high price of WINDLAS BIOTECH (WINDLAS) is ₹1,181.90, while the 52-week low is ₹697.40. Currently trading at ₹991.60, the stock is 42.19% above its 52-week low and 16.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy WINDLAS BIOTECH stock at the current price?
Whether to buy WINDLAS BIOTECH stock at ₹991.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.2 and P/B ratio of 3.63. Today's performance shows a loss of 2.97%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of WINDLAS BIOTECH and when is the next dividend?
WINDLAS BIOTECH offers a dividend yield of 0.62%, which means for every ₹100 invested at the current price of ₹991.60, you can expect to receive approximately ₹0.62 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of WINDLAS BIOTECH?
WINDLAS BIOTECH's key financial metrics include: P/E Ratio: 43.2, P/B Ratio: 3.63, ROE: 11.44%, ROCE: 11.49%, Dividend Yield: 0.62%, EPS: ₹8.55, Book Value: ₹281.47, and Debt-to-Equity: 0.05. The company's market cap stands at ₹2,062.9 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is WINDLAS BIOTECH stock performing today in the market?
WINDLAS BIOTECH stock opened at ₹1,018.40 and is currently trading at ₹991.60, showing a decline of ₹30.40 (2.97%). The intraday high is ₹1,024.50 and low is ₹979.60. The trading volume stands at 1,22,795 shares, indicating moderate market participation today.
08What is the P/E ratio of WINDLAS BIOTECH and what does it indicate?
WINDLAS BIOTECH has a Price-to-Earnings (P/E) ratio of 43.2, which means investors are willing to pay 43.20 for every ₹1 of earnings. With an EPS of ₹8.55, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about WINDLAS BIOTECH (WINDLAS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.